Which patient is going to benefit from surgical cytoreduction with intraperitoneal chemotherapy (for manifest peritoneal metastases)?
The gastric cancer with peritoneal metastases still represents a serious problem in the oncological surgery, whereas the peritoneal metastases arising from colorectal cancer can be successfully treated using a multimodal therapy concept consisting of systemic chemotherapy, cytoreductive surgery and...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2017-12-01
|
| Series: | Current Issues in Pharmacy and Medical Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/cipms-2017-0040 |
| _version_ | 1818585266365923328 |
|---|---|
| author | Blaj Sebastian Piso Pompiliu |
| author_facet | Blaj Sebastian Piso Pompiliu |
| author_sort | Blaj Sebastian |
| collection | DOAJ |
| description | The gastric cancer with peritoneal metastases still represents a serious problem in the oncological surgery, whereas the peritoneal metastases arising from colorectal cancer can be successfully treated using a multimodal therapy concept consisting of systemic chemotherapy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. The best survival rates in patients suffering from peritoneal metastases of gastric cancer have been reported by the ToGa trial, in patients with HER-2 positive expression who received standard chemotherapy and trastuzumab. Cytoreductive surgery and HIPEC are increasingly wining a place in the multimodal therapy of gastric cancer with peritoneal metastases, the criteria for such an aggressive therapy are strict and the operability needs to be previously assessed by laparoscopic exploration. Interesting new data are awaited from the German GASTRIPEC study and from the French GASTRICHIP study. |
| first_indexed | 2024-12-16T08:34:20Z |
| format | Article |
| id | doaj.art-5b49276535bd497ebddfa16e181a3ba5 |
| institution | Directory Open Access Journal |
| issn | 2084-980X 2300-6676 |
| language | English |
| last_indexed | 2024-12-16T08:34:20Z |
| publishDate | 2017-12-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Current Issues in Pharmacy and Medical Sciences |
| spelling | doaj.art-5b49276535bd497ebddfa16e181a3ba52022-12-21T22:37:48ZengSciendoCurrent Issues in Pharmacy and Medical Sciences2084-980X2300-66762017-12-0130420721010.1515/cipms-2017-0040cipms-2017-0040Which patient is going to benefit from surgical cytoreduction with intraperitoneal chemotherapy (for manifest peritoneal metastases)?Blaj Sebastian0Piso Pompiliu1Klinik für Allgemein- und Viszeralchirurgie, Krankenhaus Barmherzige Brüder Regensburg, Prüfeninger 86, 93049Regensburg, GermanyKlinik für Allgemein- und Viszeralchirurgie, Krankenhaus Barmherzige Brüder Regensburg, Prüfeninger 86, 93049Regensburg, GermanyThe gastric cancer with peritoneal metastases still represents a serious problem in the oncological surgery, whereas the peritoneal metastases arising from colorectal cancer can be successfully treated using a multimodal therapy concept consisting of systemic chemotherapy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. The best survival rates in patients suffering from peritoneal metastases of gastric cancer have been reported by the ToGa trial, in patients with HER-2 positive expression who received standard chemotherapy and trastuzumab. Cytoreductive surgery and HIPEC are increasingly wining a place in the multimodal therapy of gastric cancer with peritoneal metastases, the criteria for such an aggressive therapy are strict and the operability needs to be previously assessed by laparoscopic exploration. Interesting new data are awaited from the German GASTRIPEC study and from the French GASTRICHIP study.https://doi.org/10.1515/cipms-2017-0040peritoneal neoplasmshyperthermiainducedstomach neoplasmscytoreduction surgical proceduresinduction chemotherapylaparoscopy |
| spellingShingle | Blaj Sebastian Piso Pompiliu Which patient is going to benefit from surgical cytoreduction with intraperitoneal chemotherapy (for manifest peritoneal metastases)? Current Issues in Pharmacy and Medical Sciences peritoneal neoplasms hyperthermia induced stomach neoplasms cytoreduction surgical procedures induction chemotherapy laparoscopy |
| title | Which patient is going to benefit from surgical cytoreduction with intraperitoneal chemotherapy (for manifest peritoneal metastases)? |
| title_full | Which patient is going to benefit from surgical cytoreduction with intraperitoneal chemotherapy (for manifest peritoneal metastases)? |
| title_fullStr | Which patient is going to benefit from surgical cytoreduction with intraperitoneal chemotherapy (for manifest peritoneal metastases)? |
| title_full_unstemmed | Which patient is going to benefit from surgical cytoreduction with intraperitoneal chemotherapy (for manifest peritoneal metastases)? |
| title_short | Which patient is going to benefit from surgical cytoreduction with intraperitoneal chemotherapy (for manifest peritoneal metastases)? |
| title_sort | which patient is going to benefit from surgical cytoreduction with intraperitoneal chemotherapy for manifest peritoneal metastases |
| topic | peritoneal neoplasms hyperthermia induced stomach neoplasms cytoreduction surgical procedures induction chemotherapy laparoscopy |
| url | https://doi.org/10.1515/cipms-2017-0040 |
| work_keys_str_mv | AT blajsebastian whichpatientisgoingtobenefitfromsurgicalcytoreductionwithintraperitonealchemotherapyformanifestperitonealmetastases AT pisopompiliu whichpatientisgoingtobenefitfromsurgicalcytoreductionwithintraperitonealchemotherapyformanifestperitonealmetastases |